A “liposomal” claim is a structural claim about the delivery system, not a guaranteed performance claim. If you are qualifying an ingredient or finished product, the practical question is simple: can the supplier show method-defined evidence of liposome structure, loading, and stability under the conditions that matter for your product?
Scope note: This checklist is written for oral nutraceutical products and research-use materials marketed as “liposomal.” It focuses on buyer verification of structure and stability; it is not a regulatory guidance document. Pharma products (including IV liposomes) typically require a deeper, regulator-facing evidence package.
Key takeaways
- “Liposomal” should be treated as a claim that needs verification, not a synonym for “better absorption.”
- Decision-grade evaluation starts with analytics: structure, size distribution, loading, and stability.
- Red flags are usually documentation gaps: no methods, no stability, no batch-to-batch evidence.
What does “real liposomes” mean in practice?
“Real liposomes” means the product contains lipid bilayer vesicles that are measurable and stable enough for your intended use. In buyer terms, you are looking for evidence that the claimed structure exists in the finished product, that the active is associated with that structure (encapsulated or otherwise meaningfully retained), and that key properties remain within a defined range over shelf life.
If you need a quick reset on definitions, what ‘liposomal’ means on a spec sheet matters, and so does liposome structure (bilayer vesicles).
What evidence should you request to verify a “liposomal” claim?
Request a matched set of analytics plus the method details needed to interpret them. A single particle-size number is rarely enough.
1) Identity: do liposomes exist in the sample?
- Orthogonal evidence of vesicles and bilayer structure (for example, imaging plus a sizing method)
- Sample preparation details (dilution, buffers, filtration, temperature, time)
- What the method can and cannot distinguish (liposomes vs emulsions/micelles/aggregates)
2) Size distribution: what is the particle-size profile, and how stable is it?
- Full size distribution (not only an average)
- Measurement conditions and instrument settings
- Evidence of stability of the distribution over time and under relevant stress (temperature, agitation, freeze-thaw if applicable)
3) Loading: how much active is associated with the carrier?
Loading here means the fraction of active that is associated with the carrier under the measurement method used.
- Encapsulation or association approach and definition used
- Separation method (how free vs associated active was distinguished)
- Calculation basis and reporting units
4) Stability: does the system retain key properties through shelf life?
- Time points, storage conditions, packaging, and acceptance criteria
- What “failure” looks like (size drift, leakage, precipitation, oxidation, phase separation)
- Batch-to-batch consistency evidence (at least representative lots)
5) Fit-for-use: what does the product need to do in your format?
- Compatibility with your dosage form and process (pH, ionic strength, excipients, heat, shear)
- If oral: digestion-relevant testing can be useful, but should be framed as supportive, not definitive
What method and documentation standards should you expect?
Good data is method-defined and validated enough to support decisions. You are not asking for a perfect regulatory dossier, but you should expect the supplier to be able to explain how the numbers were generated and what they mean.
Reference standards for method development and validation include analytical procedure validation (ICH Q2(R2)) and analytical procedure development (ICH Q14)
If you need an example of a higher-bar evidence mindset for pharma, see data requirements for intravenous liposomal products.
Red flags that often indicate “liposomal” is a label, not a verified structure
Most weak “liposomal” claims fail on missing methods, missing stability, or vague language that avoids describing vesicles and bilayers.
Common red flags:
- No method details (only marketing language or a one-line spec)
- A single size number with no distribution, conditions, or repeatability
- No separation method for free vs associated active
- No stability data tied to packaging and shelf-life conditions
- No acceptance criteria (no defined pass/fail ranges)
- Claims that imply predictable bioavailability gains without ingredient- and formulation-matched evidence
Buyer checklist: what to ask for (copy/paste)
Use this list to standardize supplier qualification and compare like with like.
- What is the claimed structure (liposomes, not emulsions), and how is it demonstrated?
- What methods were used to measure size distribution, and under what conditions?
- What is the loading metric (encapsulation/association), and how was free active separated?
- What stability data exists for size distribution and loading across shelf life?
- What are the acceptance criteria for release and stability (pass/fail ranges)?
- What batch-to-batch data is available (representative lots)?
- What happens under stress relevant to our product (temperature, agitation, pH, excipients)?
- If the format is a powder or reconstitution product, what evidence shows the claimed structure after reconstitution and over time?
Where Liposoma fits
If an active is difficult, stability is fragile, or the evidence package is unclear, a practical path is often a matched analytics plan tied to your product constraints. Liposoma’s platform work (for example, LiproTeq®) is built around measurable structure, process discipline, and decision-grade data.
FAQ
Are “liposomal” claims the same as proven bioavailability improvements?
No. “Liposomal” describes a delivery structure. Any performance benefit is ingredient- and formulation-dependent and should be supported with relevant data.
Is particle size alone enough to prove a product is liposomal?
No. Particle sizing can be useful, but it does not, by itself, confirm bilayer vesicles or meaningful loading. Ask for orthogonal evidence and method details.
Are liposomal powders always fake?
Not always. The key question is whether the claimed structure exists in the product as used (for example, after reconstitution) and remains stable long enough to matter. Ask for data in the relevant format and conditions.
